Latest Dabigatran Stories
The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news.
The Firm is investigating Xarelto lawsuits on behalf of individuals who allegedly suffered uncontrollable bleeding, strokes, deep vein thrombosis, or pulmonary embolism due to the blood thinner.
Reports of Xarelto Bleeding Mounts As Doctors Are Prescribing Xarelto Over Pradaxa and Seeing a Rise In Adverse Events While Xarelto Lawsuits Begin to be Filed Reports Wright & Schulte LLC
The Firm is evaluating Xarelto lawsuits on behalf of individuals who allegedly suffered serious injuries, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism
British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading
However, Access Barriers Result in Greater Prescribing of Conventional Anticoagulants, According to Findings from Decision Resources Group BURLINGTON, Mass., July 23, 2014 /PRNewswire/ -- Decision
Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, notes that Xarelto® is surpassing Pradaxa® in the number of reported adverse events, according to the Institute for Safe
Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., June 20, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today the initiation of a new international study of Pradaxa® (dabigatran etexilate mesylate).
Boehringer Ingelheim GmbH, a German pharmaceutical company, recently announced a settlement for approximately 4,000 claims related to injuries and deaths caused by the blood thinner Pradaxa.
- Growing in low tufty patches.